Defining the Pathogenesis of Immune Deficiency in Chronic HIV Infection

定义慢性 HIV 感染免疫缺陷的发病机制

基本信息

项目摘要

DESCRIPTION (provided by applicant): This program project application is submitted by the members of the Cleveland Immunopathogenesis Consortium (CLIC) a group of investigators representing 10 academic and research institutions in the United States and Canada who have engaged for more than three years in a coordinated research effort aimed at unraveling the mechanisms whereby HIV infection results in progressive immune deficiency. This group of experienced, outstanding investigators capitalizes on complementary research skills and resources and proposes an interdisciplinary program comprising 4 projects that are coordinated and supported by two cores: Administrative Core, charged with overall coordination and administration of the program and Specimen Acquisition Core, Alan Landay, PI, charged with assuring a sustained supply of clinical specimens of gut and lymph nodes to support project investigators. The projects comprise a series of interacting research platforms from basic laboratory research to experimental animal models to translational projects, each designed to explore the determinants and mechanisms whereby immune activation drives CD4+ T cell depletion and dysfunction in chronic HIV infection. Project #1: Bystander activation drives T cell losses in chronic HIV infection - PIs: Michael M. Lederman, M.D., Scott F. Sieg Ph.D. - Case, will test the hypothesis that increased systemic levels of microbial TLR ligands and common gamma chain cytokines in secondary lymphoid tissues drive central memory T cell activation and turnover in chronic HIV infection. Project #2: Loss of intestinal barrier function in HIV infection - Alan Levine, Ph.D. Case, will examine the integrity of the intestinal mucosa in HIV infection to document the mechanistic details underlying the enhanced translocation of microbial products through the damaged gut that we propose contributes to the pathogenesis of cell loss in chronic HIV infection. Project #3: Immune activation and AIDS pathogenesis in SIV-infected non-human primates - Guido Silvestri, M.D., Univ of Pennsylvania, will attempt to induce disease in non-pathogenic SIV infection of sooty mangabeys by activation of the innate immune system and will test whether blocking innate immune activation will attenuate disease pathogenesis in infected rhesus macaques. Project #4: Immune activation promotes PD1 expression and immune dysfunction in chronic HIV infection - Rafick Pierre Sekaly Ph.D. - Univ of Montreal, will examine the role of innate immune system activation through the interaction between HIV RNAs and TLR7/8 on the expression of PDL-1 and 2 and their effects on the function and survival of HIV reactive T cells.
描述(由申请人提供):该计划项目申请是由克利夫兰免疫病变联盟(CLIC)的成员提交的一组研究人员,代表了美国和加拿大的10家学术和研究机构,他们从事了三年以上的研究工作,该研究旨在揭示HIV HIV Infictight in Callessive Sefune in Callessive Invefiction Sefune Sefection Sefune Sefune sealtive Insvience in Callistive Insune sealtive farne sealige seftive hivefection。 This group of experienced, outstanding investigators capitalizes on complementary research skills and resources and proposes an interdisciplinary program comprising 4 projects that are coordinated and supported by two cores: Administrative Core, charged with overall coordination and administration of the program and Specimen Acquisition Core, Alan Landay, PI, charged with assuring a sustained supply of clinical specimens of gut and lymph nodes to support project investigators.这些项目包括一系列相互作用的研究平台,从基础实验室研究到实验动物模型再到转化项目,每个项目旨在探索决定因素和机制,免疫激活驱动CD4+ T细胞的耗竭和慢性HIV感染功能障碍。项目#1:旁观者激活驱动慢性艾滋病毒感染中的T细胞损失-PIS:Michael M. Lederman,M.D。,Scott F. Sieg Ph.D. - 案例将检验以下假设:在次级淋巴组织中,微生物TLR配体的全身水平和常见的γ链细胞因子驱动中心记忆T细胞激活和慢性HIV感染中的周转率。项目#2:HIV感染中肠道屏障功能的丧失-Alan Levine,Ph.D。案例,将检查肠道粘膜在HIV感染中的完整性,以记录通过肠道受损的肠道增强微生物产物易位的机械细节,我们提出的这有助于慢性HIV感染中细胞丧失的发病机理。项目#3:宾夕法尼亚州大学的SIV感染的非人类灵长类动物的免疫激活和辅助发病机制 - Guido Silvestri,M.D.项目#4:免疫激活促进慢性HIV感染中的PD1表达和免疫功能障碍-Rafick Pierre Sekaly Ph.D. - 蒙特利尔大学将通过HIV RNA和TLR7/8之间的相互作用来研究先天免疫系统激活的作用,对PDL-1和2的表达及其对HIV反应性T细胞功能和存活的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL MARCEL LEDERMAN其他文献

MICHAEL MARCEL LEDERMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL MARCEL LEDERMAN', 18)}}的其他基金

Targeting Cytolytic Cells to Lymphoid Sites of HIV Persistence.
将溶细胞细胞靶向 HIV 持续存在的淋巴部位。
  • 批准号:
    9292706
  • 财政年份:
    2016
  • 资助金额:
    $ 194.93万
  • 项目类别:
Targeting Cytolytic Cells to Lymphoid Sites of HIV Persistence.
将溶细胞细胞靶向 HIV 持续存在的淋巴部位。
  • 批准号:
    8841193
  • 财政年份:
    2014
  • 资助金额:
    $ 194.93万
  • 项目类别:
Targeting Cytolytic Cells to Lymphoid Sites of HIV Persistence.
将溶细胞细胞靶向 HIV 持续存在的淋巴部位。
  • 批准号:
    8930055
  • 财政年份:
    2014
  • 资助金额:
    $ 194.93万
  • 项目类别:
Effects of IL-6 blockade in treated HIV infection
IL-6 阻断对 HIV 感染治疗的影响
  • 批准号:
    8617799
  • 财政年份:
    2013
  • 资助金额:
    $ 194.93万
  • 项目类别:
Effects of IL-6 blockade in treated HIV infection
IL-6 阻断对 HIV 感染治疗的影响
  • 批准号:
    9005805
  • 财政年份:
    2013
  • 资助金额:
    $ 194.93万
  • 项目类别:
Effects of IL-6 blockade in treated HIV infection
IL-6 阻断对 HIV 感染治疗的影响
  • 批准号:
    8510992
  • 财政年份:
    2013
  • 资助金额:
    $ 194.93万
  • 项目类别:
Basic and Comparative Studies of CCR5 Inhibition to Prevent HIV Transmission
抑制 CCR5 预防 HIV 传播的基础和比较研究
  • 批准号:
    7391001
  • 财政年份:
    2008
  • 资助金额:
    $ 194.93万
  • 项目类别:
Developing RANTES analogues as topical strategies to prevent HIV transmission
开发 RANTES 类似物作为预防 HIV 传播的局部策略
  • 批准号:
    7418081
  • 财政年份:
    2008
  • 资助金额:
    $ 194.93万
  • 项目类别:
Defining the Pathogenesis of Immune Deficiency in Chronic HIV Infection
定义慢性 HIV 感染免疫缺陷的发病机制
  • 批准号:
    7666054
  • 财政年份:
    2008
  • 资助金额:
    $ 194.93万
  • 项目类别:
Basic and Comparative Studies of CCR5 Inhibition to Prevent HIV Transmission
抑制 CCR5 预防 HIV 传播的基础和比较研究
  • 批准号:
    7879534
  • 财政年份:
    2008
  • 资助金额:
    $ 194.93万
  • 项目类别:

相似国自然基金

具核梭杆菌通过抑制Synbindin促进肠免疫原DC/Th17分化在克罗恩病发病中的机制研究
  • 批准号:
    82370535
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
TIGIT受体信号调控Tregs活性参与脓毒症免疫应答紊乱发病的机制研究
  • 批准号:
    82302409
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
牙龈卟啉单胞菌通过牙龈素降解CD19引发B细胞免疫失衡加剧类风湿性关节炎发病的机制研究
  • 批准号:
    82370969
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
基于线粒体Akt-PGC1α-TFAM通路介导的血小板调控CD4+T细胞免疫应答促进再障发病的机制研究
  • 批准号:
    82300161
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
糖蛋白A重复优势蛋白介导T细胞免疫耐受失衡在原发免疫性血小板减少症发病中的作用和机制研究
  • 批准号:
    82370132
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目

相似海外基金

Defining single-channel paracellular (tight junction) conductances using nanotechnology
使用纳米技术定义单通道旁细胞(紧密连接)电导
  • 批准号:
    10593421
  • 财政年份:
    2023
  • 资助金额:
    $ 194.93万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 194.93万
  • 项目类别:
Defining the impact of Extracellular Vesicles on inflammation during pneumonic plague
定义细胞外囊泡对肺鼠疫期间炎症的影响
  • 批准号:
    10750181
  • 财政年份:
    2023
  • 资助金额:
    $ 194.93万
  • 项目类别:
Defining astrovirus-specific T cell responses
定义星状病毒特异性 T 细胞反应
  • 批准号:
    10667003
  • 财政年份:
    2023
  • 资助金额:
    $ 194.93万
  • 项目类别:
BCCMA: Targeting Osteoarthritis Pain and Progression: Defining biologic and inflammatory markers associated with rapid progression
BCCMA:针对骨关节炎疼痛和进展:定义与快速进展相关的生物和炎症标志物
  • 批准号:
    10486497
  • 财政年份:
    2023
  • 资助金额:
    $ 194.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了